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The incidence of B cell non-Hodgkin lymphoma (NHL) is
increased substantially in the HIV-1-infected immuno-
suppressed population. Clinically, AIDS-related lym-
phoma (ARL) is more aggressive and has a worse
prognosis than in non-immunocompromised patients,
though there has been significant improvement in the
post-HAART era. While HIV-induced immunosuppres-
sion, chronic antigenic stimulation, and cytokine over-
production may contribute to differences in disease
progression and outcome, distinct genetic changes in ARL
may also mediate these effects. Chromosomal DNA copy
number alterations are known to play a major role in lym-
phomagenesis and have been studied in non immuno-
compromised patients for some NHLs.
To determine whether ARL has distinct molecular features
and pathogenetic mechanisms, we assessed genome-wide
copy number changes and gene expression profiles using
24 HIV+ cases with B cell NHL obtained from the AIDS
and Cancer Specimen Resource (ACSR). High resolution
aCGH was performed using the 250 K NspI SNP platform
(Affymetrix). Selecting for frequent aberrations present in
>20 percent of the cases, 43 chromosomal gains and 30
chromosomal losses were identified. Many of these
regions replicated copy number changes previously
reported for high-grade B cell NHL, including: gains of X,
12, 11q, 8q, 2p16.1, 9p11.2, 17q21, and 3p; and losses of
1p36, 4q23, 9p21.3, 13q34, and 17q23. The aberrant
regions ranged in size from 12 kb to 6.5 Mb, providing
concise boundaries for these intervals, which harbor a rel-
atively small number of genes. Several novel recurrent
regions were also identified, including a loss of 7q21.2–
q22.1, and gains of 4p16.1, 15q11.2, and 19p13.2. To
identify coordinate changes in gene expression associated
with the chromosomal aberrations, gene expression pro-
files were generated using the Human Genome U133 Plus
2.0 Array (Affymetrix). This approach identified specific
candidate genes for these intervals that may contribute to
ARL pathogenesis. Gene expression profiles were also
used to cluster the ARL cases. Gene signatures that reliably
distinguish activated B-cell (ABC) like Diffuse Large B Cell
Lymphoma (DLBCL), germinal center B-cell (GCB) like
DLBCL and Burkitt lymphoma (BL), were applied to the
ARL gene expression profiles.
The ARL samples showed no correlation with the BL gene
signature. In contrast, the ABC and GCB gene signatures
divided the ARL samples into two distinct groups with
either a predominantly ABC- or GCB-type expression.
Assigning ABC and GCB phenotypes to these groups of
samples, Goeman's global test found a highly significant
association (p = 0.00012) of the ABC and GCB pheno-
types with the DLBCL ABC and GCB predictor gene set.
The classification of AIDS-related DLBCLs into distinct
ABC and GCB groups has significant implications given
the differences in pathogenesis, biology, and survival for
these two subtypes of DLBCL.
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